MedTrace Logo

An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART

NCT01541085 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 33

Last updated 2013-11-26

No results posted yet for this study

Summary

The purpose of this study is to study the kinetics (study of the rate of change) of immune recovery quality and function in stored plasma blood samples of treatment-naive (not previously treated with antiretroviral drugs) patients with advanced human immunodeficiency virus (HIV) infection starting a Darunavir/Ritonavir- or Efavirenz-based highly active antiretroviral therapy (HAART) regimen.

Conditions

  • Human Immunodeficiency Virus; HIV

Interventions

DRUG

Darunavir/Ritonavir (DRV/r)

Darunavir/Ritonavir (DRV/r) + Tenofovir/Emtricitabina regimen

DRUG

Efavirenz (EFV)

Efavirenz (EFV) + Tenofovir/Emtricitabina regimen

Sponsors & Collaborators

  • Janssen-Cilag S.p.A.

    lead INDUSTRY

Principal Investigators

  • Janssen-Cilag S.p.A., Italy Clinical Trial · Janssen-Cilag S.p.A.

Eligibility

Min Age
30 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2013-06-30
Completion
2013-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01541085 on ClinicalTrials.gov